Nasdaq Nordic’s 57th listing, Farfetch valuation at $8.6bn from NYSE IPO, Dell to IPO, Denmark’s StenoCare IPOs for medicinal cannabis surge…

Nasdaq First North in Stockholm is hosting the IPO today of Asarina Pharma, making it the 57th company to list on the Nasdaq Nordic markets this year. The Swedish-based biotech company has developed the world’s first dedicated treatment for premenstrual dysphoric disorder (PMDD) and other menstrual-related conditions. Erik Penser Bank AB is the Certified Adviser for the deal.

London-based online fashion retailer Farfetch had its shares trading around 50 per cent higher in its NYSE IPO last Friday, trading as high as US$30.60 per share from opening at US$20 per share, reports the Financial Times. This valued the Shoreditch-based company up to US$8.6 billion. Farfetch is an online platform that sells boutique and luxury brands worldwide, such as Prada and Gucci. The Company is yet to turn a profit but the market itself is rapidly growing.

Dell Technologies Inc is looking to have an IPO rather than listing through a proposed acquisition, reports the New York Times. Dell was going to undertake a share buy back for VMware this week but postponed the roadshow for VMware. This would have allowed Dell to bypass its US$52.7 billion in debt through its IPO, so investors in the Company are now drawing concern with the new plan.  

Danish-based medicinal cannabis company StenoCare is planning an IPO to take advantage of the rapidly growing industry, reports the New York Times. StenoCare was thee first Danish company to get permission to import, produce and sell cannabis oil in Denmark. It will use the proceeds to build its own production facility to help supply the growing demand for the product throughout Europe.  

The Oslo-based co-owner of Daft and DoneDeal, Schibsted, is planning to spin off Daft and DoneDeal to form a new company called MPI to IPO it, reports The Sunday Times. Schibsted said it will retain a majority holding after the IPO and cited its strong position in Ireland as a key asset.

Abchurch has been party to 94 IPOs and as such is the leading London Financial PR and Investor Relations adviser for new listings of growth companies. The earlier we get to talk to the Company the better the result. No fund manager likes to be shown the best thing since sliced bread if it has no profile and no-one has ever heard of the company! So do get in touch. 

[email protected] Email me to receive a complimentary daily Abchurch IPO Insight, which covers IPOs and M&A from around the world, providing vital comparators for deal metrics and valuations. Today’s Insight feed will give you direct links to relevant articles from around the world. To stay up-to-date with global IPO news, follow Abchurch on LinkedIn and Twitter. 

Abchurch IPO Insight is a white-label version of Citywebwatch’s Dealsreader, which is the only daily round-up of global IPO news from established newspaper sources. Click here for an immediate free Citywebwatch Dealsreader trial.